Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

79 trials with published results (16%)

Research Maturity

372 completed trials (77% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.9%

9 terminated out of 481 trials

Success Rate

97.6%

+11.1% vs benchmark

Late-Stage Pipeline

7%

33 trials in Phase 3/4

Results Transparency

21%

79 of 372 completed with results

Key Signals

79 with results98% success

Data Visualizations

Phase Distribution

430Total
Not Applicable (45)
Early P 1 (8)
P 1 (328)
P 2 (16)
P 3 (3)
P 4 (30)

Trial Status

Completed372
Unknown55
Recruiting22
Withdrawn11
Terminated9
Not Yet Recruiting7

Trial Success Rate

97.6%

Benchmark: 86.5%

Based on 372 completed trials

Clinical Trials (481)

Showing 20 of 20 trials
NCT03737292Phase 4Recruiting

Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy

NCT06500793Phase 1RecruitingPrimary

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT07583407Not ApplicableRecruiting

Pharmacokinetics of Kava and Kratom Alone and in Combination

NCT07560150Phase 2RecruitingPrimary

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT04669717Phase 4Recruiting

Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies

NCT05328778Phase 4CompletedPrimary

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

NCT07422285Phase 1Recruiting

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT05041699Phase 1CompletedPrimary

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

NCT05539872Phase 2CompletedPrimary

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT04961593RecruitingPrimary

PK/PD of Caspofungin in Children Severe Infection

NCT07102095Phase 1Completed

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

NCT07312643Phase 1CompletedPrimary

Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

NCT06854783Phase 1CompletedPrimary

Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

NCT06665555Phase 1CompletedPrimary

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

NCT06480981Phase 1CompletedPrimary

Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers

NCT06426836Not ApplicableRecruitingPrimary

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

NCT02456974RecruitingPrimary

Antibiotic Dosing in Pediatric Intensive Care

NCT07285967Phase 1Not Yet Recruiting

A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

NCT06733675Phase 1Recruiting

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06921590Phase 1Active Not RecruitingPrimary

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

Scroll to load more

Research Network

Activity Timeline